Loading...
•
Mar 31, 2020
Allogene Q1 2020 Earnings Report
Reported first quarter financial results and provided a corporate update.
Key Takeaways
Allogene Therapeutics reported its first quarter financial results, highlighting progress in its AlloCAR T therapy development, including upcoming presentations and trial initiations. The company ended the quarter with $553 million in cash, cash equivalents, and investments.
Initial results from the Phase 1 ALLO-501 ALPHA trial in relapsed/refractory non-Hodgkin lymphoma will be presented at ASCO.
The Phase 1 ALPHA2 trial for ALLO-501A is on track to initiate in Q2 2020.
Initial data from the Phase 1 ALLO-715 UNIVERSAL trial in relapsed/refractory multiple myeloma is expected in Q4 2020.
Preclinical findings supporting TurboCAR™ Technology will be presented at ASGCT 2020.
Forward Guidance
Allogene expects full year GAAP net losses to be between $260 million and $280 million, including estimated non-cash stock-based compensation expense of $70 million to $75 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...